Retrospective analysis of the efficacy of BTK inhibitors in the treatment of different types of B-cell lymphoma
Objective To compare the efficacy of different BTK inhibitors on various types of B-cell lymphoma and provide reference for optimizing therapy.Methods Clinical data including PET/CT,tumor marker detection,adverse reactions and medication regimens were collected from patients with B-cell lymphoma.The patients were grouped according to the type of lymphoma and different regimens.The efficacy and incidence of ibrutinib,zanubrutinib,and orelabrutinib on chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL),diffuse large B-cell lymphoma(DLBCL)and mantle cell lymphoma(MCL)were compared.Results For CLL/SLL,orelabrutinib ORR was 70.59%,zanubrutinib ORR was 64.52%,ibrutinib ORR was 45.00%.For DLBCL,the regimen in the study was BTK inhibitor combined with R+CHOP,with an ORR of 54.55%for orelabrutinib,47.62%for zanubrutinib and 41.67%for ibrutinib.For MCL,zanubrutinib ORR was 81.82%,orelabrutinib ORR was 71.43%and ibrutinib ORR was 62.50%.The three BTK inhibitors could reduce β2-MG level,among them,orelabrutinib could significantly reduce the serum concentration β2-MG of CLL/SLL,DLBCL and MCL(P＜0.05).In terms of the adverse reactions,diarrhea,respiratory infections and muscle soreness showed the lowest rate in patients with CLL/SLL,DLBCL,MCL who were treated with orelabrutinib,and among the MCL patients,orelabrutinib treating had the lowest diarrhea incidence,and the difference was statistically significant(P＜0.05).Neutropenia,thrombocytopenia,and anemia during the treatment of three BTK inhibitors were not significantly different within the same disease group.Conclusion Orelabrutinib showed the highest therapeutic effect on CLL/SLL,zanubrutinib showed the best therapeutic effect on MCL.The efficacy of three BTK inhibitor combined with R+CHOP in the treatment of DLBCL was similar,with slightly higher levels of orelabrutinib.Comprehensive comparison of the incidence of various adverse,orelabrutinib showed the best safety.
万方数据
维普
